Key result
The Ser49Gly variant in the beta1-adrenergic receptor gene was associated with decreased mortality or hospitalization compared to the wild type in heart failure patients (39% vs 62%; P=0.005).
Why the study?
Does the Ser49Gly variant in the beta1-adrenergic receptor gene improve survival in patients with congestive heart failure?
Observational (n=261)
Does the Ser49Gly variant in the beta1-adrenergic receptor gene improve survival in patients with congestive heart failure?
Effect estimate: RR 2.34 (95% CI 1.30-4.20)
Absolute Event Rate: 39% vs 62%
p-value: p=0.003
The Ser49Gly variant in the beta1-adrenergic receptor gene is associated with a decreased mortality risk in patients with congestive heart failure, suggesting a potential cardioprotective effect.
No takes yet. Share an insight, caveat, or question.
Ser49Gly variant was associated with better HF outcomes; hypothesis-generating and requires prospective validation before clinical adoption.
Mats Börjesson (2000) conducted an observational in congestive heart failure (n=261). Ser49Gly variant in the beta1-adrenergic receptor gene vs. Wild type gene was evaluated on Death or hospitalization (RR 2.34, 95% CI 1.30-4.20, p=0.003). The Ser49Gly variant in the beta1-adrenergic receptor gene was associated with decreased mortality or hospitalization compared to the wild type in heart failure patients (39% vs 62%; P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: